Irreversible tyrosine kinase inhibitors of epidermal growth factor receptors family – a new, promising therapeutic strategy
Journal Title: OncoReview - Year 2012, Vol 2, Issue 1
Abstract
Inhibitors of tyrosine kinase residues of epidermal growth factor receptor family (ErbB) have became a treatment of choice in many tumor types. However, even in the presence of predictive factors some patients completely do not benefit from this kind of therapy and basically all responding patients will ultimately develop resistance. Detailed characterization of function and signaling of ErbB receptors revealed that reversible blockade of those receptors represented one of potential escape mechanisms from this particular molecular intervention. Following this observation has several companies generated a novel class of drugs – irreversible ErbB-receptors tyrosine kinase inhibitors. Preclinical and clinical research demonstrated that complete and irreversible blockade of ErbB receptors efficiently inhibited signaling pathways responsible for growth and progression of malignant process leading to objective responses in advanced cancer patients. This article aims to review promising clinical data on the use of irreversible tyrosine kinasase inhibitors in various malignancies with a special focus on lung and breast cancer.
Authors and Affiliations
Piotr Wysocki
Keywords
Related Articles
- EP ID EP53134
- DOI -
- Views 228
- Downloads 0
Management strategy of patients with chronic myeloid leukemia in chronic phase who failed to response to imatinib – Kraków Haematology Clinic experience
Introduction: Tyrosine kinase inhibitors eliminate chronic myeloid leukemia cells in a targeted way. The resistance to this therapy was the cause of development of treatment recommendations and drugs of second and subseq...
Role of molecular examinations in qualification to first line treatment with erlotinib in NSCLC patients based on EURTAC study results
Between 2010–2011 the first EGFR thyrosine kinase inhibitor (EGFR TKI) – gefitinib, was registered in many countries in I line of treatment in patients with advanced and locally advanced non-small cell lung cancer (NSCLC...
Irreversible tyrosine kinase inhibitors of epidermal growth factor receptors family – a new, promising therapeutic strategy
Inhibitors of tyrosine kinase residues of epidermal growth factor receptor family (ErbB) have became a treatment of choice in many tumor types. However, even in the presence of predictive factors some patients completely...
Pericardiocentesis and pericardial therapy aspects in cancer patients - a case report
The malignancy related pericardial effusion has variable dynamics, and the clinical presentation and severity of symptoms are directly related to the degree of hemodynamic conditions and the rate of fluid accumulation in...
Antyproliferacyjne działanie analogów somatostatyny - przesłanie z badania PROMID